Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study

Alan H B Wu, Milton Packer, Andrew Smith, Rachel Bijou, Daniel Fink, Johannes Mair, Lars Wallentin, Nina Johnston, Carolyn S. Feldcamp, Doris M. Haverstick, Charaf E. Ahnadi, Andrew Grant, Normand Despres, Barry Bluestein, Farooq Ghani

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Background: B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF). Methods: We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur® BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA™ and Biosite Triage® BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV). Results: The ADVIA Centaur assay had total imprecision (CV) of 3.4%, 2.9%, and 2.4% at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r = 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L (r = 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased. Conclusions: The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF.

Original languageEnglish (US)
Pages (from-to)867-873
Number of pages7
JournalClinical Chemistry
Volume50
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Brain Natriuretic Peptide
Assays
Heart Failure
Triage
Blood
Edetic Acid
Plastics
Limit of Detection
Immunochemistry
Pulmonary diseases
Hooks
Medical problems
Neuropeptides
Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Stretching
Heart Ventricles
Renal Insufficiency
Chronic Disease
Gels

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure : A multisite study. / Wu, Alan H B; Packer, Milton; Smith, Andrew; Bijou, Rachel; Fink, Daniel; Mair, Johannes; Wallentin, Lars; Johnston, Nina; Feldcamp, Carolyn S.; Haverstick, Doris M.; Ahnadi, Charaf E.; Grant, Andrew; Despres, Normand; Bluestein, Barry; Ghani, Farooq.

In: Clinical Chemistry, Vol. 50, No. 5, 05.2004, p. 867-873.

Research output: Contribution to journalArticle

Wu, AHB, Packer, M, Smith, A, Bijou, R, Fink, D, Mair, J, Wallentin, L, Johnston, N, Feldcamp, CS, Haverstick, DM, Ahnadi, CE, Grant, A, Despres, N, Bluestein, B & Ghani, F 2004, 'Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study', Clinical Chemistry, vol. 50, no. 5, pp. 867-873. https://doi.org/10.1373/clinchem.2003.026138
Wu, Alan H B ; Packer, Milton ; Smith, Andrew ; Bijou, Rachel ; Fink, Daniel ; Mair, Johannes ; Wallentin, Lars ; Johnston, Nina ; Feldcamp, Carolyn S. ; Haverstick, Doris M. ; Ahnadi, Charaf E. ; Grant, Andrew ; Despres, Normand ; Bluestein, Barry ; Ghani, Farooq. / Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure : A multisite study. In: Clinical Chemistry. 2004 ; Vol. 50, No. 5. pp. 867-873.
@article{def7e53dcc234e06a0792dd07eb11353,
title = "Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study",
abstract = "Background: B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF). Methods: We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur{\circledR} BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA™ and Biosite Triage{\circledR} BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV). Results: The ADVIA Centaur assay had total imprecision (CV) of 3.4{\%}, 2.9{\%}, and 2.4{\%} at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r = 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L (r = 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased. Conclusions: The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF.",
author = "Wu, {Alan H B} and Milton Packer and Andrew Smith and Rachel Bijou and Daniel Fink and Johannes Mair and Lars Wallentin and Nina Johnston and Feldcamp, {Carolyn S.} and Haverstick, {Doris M.} and Ahnadi, {Charaf E.} and Andrew Grant and Normand Despres and Barry Bluestein and Farooq Ghani",
year = "2004",
month = "5",
doi = "10.1373/clinchem.2003.026138",
language = "English (US)",
volume = "50",
pages = "867--873",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "5",

}

TY - JOUR

T1 - Analytical and clinical evaluation of the bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure

T2 - A multisite study

AU - Wu, Alan H B

AU - Packer, Milton

AU - Smith, Andrew

AU - Bijou, Rachel

AU - Fink, Daniel

AU - Mair, Johannes

AU - Wallentin, Lars

AU - Johnston, Nina

AU - Feldcamp, Carolyn S.

AU - Haverstick, Doris M.

AU - Ahnadi, Charaf E.

AU - Grant, Andrew

AU - Despres, Normand

AU - Bluestein, Barry

AU - Ghani, Farooq

PY - 2004/5

Y1 - 2004/5

N2 - Background: B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF). Methods: We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur® BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA™ and Biosite Triage® BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV). Results: The ADVIA Centaur assay had total imprecision (CV) of 3.4%, 2.9%, and 2.4% at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r = 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L (r = 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased. Conclusions: The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF.

AB - Background: B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF). Methods: We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur® BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA™ and Biosite Triage® BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV). Results: The ADVIA Centaur assay had total imprecision (CV) of 3.4%, 2.9%, and 2.4% at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r = 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L (r = 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased. Conclusions: The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF.

UR - http://www.scopus.com/inward/record.url?scp=11144358465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358465&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2003.026138

DO - 10.1373/clinchem.2003.026138

M3 - Article

C2 - 15010423

AN - SCOPUS:11144358465

VL - 50

SP - 867

EP - 873

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 5

ER -